Auteur/autrice : jberthold

BIOASTER

by jbertholdin Biotech, Pharma

BIOASTER

About the company

BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD.
With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships.
Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.

About the solution

Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.

Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.

Website
Key information

– Therapeutic areas: Infectious & therapeutic vaccines, Immunology, Auto-immune diseases, Inflammatory diseases, Immuno-modulation, Microbiota, Antimicrobial, Antiviral, Ivd, Support to bioprocess optimization & bioproduction, Support to cmc

– Based in: Paris & Lyon (FRANCE)

– Employees: 51 – 200

– Created in: 2012

PORSOLT

by jbertholdin Institutions, Service Providers & others

PORSOLT

About the company

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 40 years, covering the drug development process from early screening through regulatory submission.

About the solution

Porsolt provides discovery and preclinical services (safety & efficacy) including in vitro assays, pathophysiological models in multiple species and cell lines, customized procedures, and tailored solutions. They offer to support drug development using high throughput screening, high content analysis, and high content histology platforms, drug formulation analysis, and bioanalytical services.

Their vast expertise covers the following areas: psychiatric and neurological disorders, cardiac and vascular diseases, oncology, pain, inflammation, gastrointestinal disorders, liver diseases, metabolic and eating disorders, respiratory diseases, dermatology, medical devices, and predictive toxicity of compounds.

Website
Key information

–  Therapeutic areas: Cardiovascular System, Central Nervious System,Dermatology,Gastrointestinal System,Histoilogy, Inflammation, Liver & Hepatic System,Medical Devices,Obesity & Metabolic Disorders, Oncology,Pain, Pharmacokinetics, Predictive Toxicity, Respiratory System, Safety Regulatory Package, Thrombosis/ Blood, Urogenital System,Biomarkers Assays, Cell & Tissue Banks,Formulation Analysis, Image Processing & Data Analysis,Technical Skills,Technical Capabilities.

–  Based in: Le Genest Saint Isle (FRANCE)

–  Employees: 51 – 200

–  Created in: 1940

AP-HP PARIS

by jbertholdin Institutions, Service Providers & others

AP-HP (Greater Paris University Hospitals)

About the company

Assistance Publique – Hôpitaux de Paris is the leading university hospital center in Europe. With three missions, to care, to train, to research and to innovate, the AP-HP takes care of all the people who come to its hospitals, trains the professionals of today and tomorrow and is a major player in research.

About the solution

The AP-HP, through its status as a university hospital, has the mission to innovate. The search for new solutions to contribute to the well-being of patients, their loved ones and the professionals who support them is one of its primary missions. It supports and accompanies several forms of health innovation whoever it is.

Website
Key information

–  Therapeutic areas: Neurology, Cancerology, Immunology etc…

–  Based in: Paris (FRANCE)

–  Employees: 500+

–  Created in: 1900

AURORA STERILISATION

by jbertholdin Medtech

AURORA STERILISATION

About the company

Aurora was founded in 2019 by Jan Laarman and Thomas Parias, after 5 years of in-house industrial research, two entrepreneurs passionate about innovation in the field of healthcare. Their goal is to become a major player in the field of sterilization using natural plasma as the sole sterilizing agent.

About the solution

The company develops a unique patent-protected sterilization method based on an oxygen plasma. It enables the sterilization of complex and sensitive devices that can’t be sterilized with existing technologies. It operates at low temperature (30-40°C). It is an environmental-friendly sterilization technology of medical devices.

Website
Key information

–  Therapeutic areas: Endoscopy, Prosthetics, Sterilization

–  Based in: Rouen & Reims (FRANCE)

–  Employees: 11 – 50

–  Created in: 2019

BIOVALLEY FRANCE

by jbertholdin Institutions, Service Providers & others

BIOVALLEY FRANCE

About the company

Based in Eastern France, the BioValley France cluster brings to the health sector its unique expertise and personalized support around 4 fields of expertise: Drugs and Innovative Therapies, E-health, Medical Technologies and Diagnosis. For more than eighteen years, BioValley France has built a powerful community in order to deploy a strong network mixing academics and industrials in the health sector: more than 300 members and partners have decided to join the Cluster in order to share, exchange and develop tomorrow’s innovation in the best conditions. BioValley France offers services in: Business Competitiveness, Innovative Project, International Relations, Visibility and Influence.

About the solution

For more than eighteen years, BioValley France has built a powerful community in order to deploy a strong network mixing academics and industrials in the health sector: more than 300 members and partners have decided to join the Cluster in order to share, exchange and develop tomorrow’s innovation in the best conditions.

Website
Key information

–  Therapeutic areas: Medical Device, E-health, Biotherapy

–  Based in: Strasbourg (FRANCE)

–  Employees: 11 – 50

–  Created in: 2002

RONDOL INDUSTRIE

by jbertholdin Biotech, Medtech, Pharma

RONDOL INDUSTRIE

About the company

Rondol Industrie have been created in 2012 with the goal of adapting hot melt extrusion technology to the micro scale and to Pharma standards, thereby contributing to better and cheaper healthcare.

Their team aims to leverage their combined 60 years of experience in extrusion technologies to offer a range of energy-efficient machines that would enable pharmaceutical companies to conduct trials and manufacture in better and cheaper formulations.

Along the way, they realized that their extrusion machines were capable of much more than initially expected. They can now produce a diverse range of extruded products via custom dies.

About the solution


Best of all, their vertical extruders are much smaller than traditional machines, saving on expensive footprint and material costs. Ease of cleaning also enables a quick turnaround between production lots or trials.

They are proud of what they have achieved so far – ground-breaking improvements in the bioavailability of aspirin for cancer treatment and reformulation of anti-malarial drugs to be suitable for children, among numerous other drug and medical implant trials. They are growing partnerships with industry and academia in Canada, England, France, Germany, Northern Ireland, and the USA. They have twice been nominated for a Galien Award in 2020 and 2023.

Website
Key information

–  Therapeutic areas: Hot Melt Extruders for Drug Formulation and Medical Device

–  Based in: Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2012

ERBC GROUP

by jbertholdin Institutions, Service Providers & others

ERBC GROUP

About the company

ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.

About the solution

At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS:
– Build on most relevant translational models
– Select best predictive biomarkers
– Choose state-of-the-art technologies.

Website
Key information

–  Therapeutic areas: Oncology – Cancer, Immunology, Inflammation, Neurology – Neurosciences, Cell and gene therapies, Cardiovascular, Infectious diseases, Metabolic diseases – Hepatology – Diabetes, Gastroenterology, Respiratory, Ophthalmology, Allergy, Dermatology, Orthopedics, Central nervous system, Nephrology, Cardiology, Pulmonology, Endocrinology, Hematology

–  Based in: Baugy, Toulouse, Lyon, Orleans (FRANCE)

–  Employees: 201-500

–  Created in: 2019

SEQENS

by jbertholdin Biotech, Pharma

SEQENS

About the company

SEQENS is a global partner in health, personal care and specialty ingredients. They empower innovation to bring the best solutions to our customers, with a constant concern for sustainability. Relying on the skills of 3300 employees, they leverage a worldwide manufacturing network, and state-of-the-art R&D centers.
As an end-to-end player across the value chain, SEQENS offers a broad range of active ingredients, pharmaceutical intermediates, personal care & specialty ingredients. They innovate, develop and industrialize the most demanding molecules, and implement the best available technologies.

As a leading player of the health industry, SEQENS is committed to the therapies of the future and personalized medicine.

Driven by a culture of excellence and a strong entrepreneurial spirit, they share values such as unity, agility, and reactivity. They provide the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance to our strong CSR program.

About the solution

Streamline your development process with Seqens’ one-stop-shop CDMO services. They offer integrated support for all stages of your program, from discovery and preclinical studies to clinical development, market authorization, and even ongoing commercial manufacturing. This ensures seamless handoffs and reduces overall development timelines.

Website
Key information

– Therapeutic areas: Oncology

– Based in: Ecully (FRANCE) & Devens (Boston, US)

– Employees: 500+

– Created in: 2003

OXELTIS

by jbertholdin Institutions, Service Providers & others

OXELTIS

About the company

Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.

About the solution

Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.

Website
Key information

–  Therapeutic areas: Infectious diseases, antivirals, antibacterials, Oncology, Neurology, CNS

–  Based in: Montpellier (FRANCE)

–  Employees: 11 – 50

–  Created in: 2010

MAAT PHARMA

by jbertholdin Biotech, Pharma

MAAT PHARMA

About the company

MaaT Pharma is the leading microbiome company in oncology.
The Company owns in-house cGMP manufacturing capacities and specializes in developing Microbiome Ecosystem Therapies dedicated to enhancing the survival of cancer patients, with a focus on treating and preventing complications in blood cancers and improving treatments in immuno-oncology.

About the solution

MaaT013, a pooled-donor microbiome ecosystem therapy, is a non-immunosuppressive treatment dedicated to treat acute GvHD.
As of today, MaaT013 has been administered to more than 200 patients.
A Phase 3 trial is currently ongoing with ORR results expected in mid-2024.
The Company has an open-IND granted by the U.S. FDA and has engaged active discussions with prominent US clinicians in the field of stem cell transplantation to explore the most efficient path forward to introduce MaaT013 to patients in the United States.
MaaT013 has been awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

MaaT033, a donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing is currently ongoing Phase 2 as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies.
MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA) in August 2023.

Website
Key information

– Therapeutic areas: Oncology, Hemato-Oncology: acute Graft-versus-Host Disease (aGvHD), allogenic hematopoietic stem cell transplantation; Immuno-oncology: metastatic melanoma; Neurodegenerative diseases : Amyotrophic lateral sclerosis (ALS).

– Based in: Lyon (FRANCE)

– Employees: 51-200

– Created in: 2014